Reata Pharmaceuticals - Top 15 Biotech VC Deals of 2010 - FierceBiotech PDF Print
FierceBiotech
But in the course of clinical trials, researchers noticed improved renal function in subjects who were given the drug, prompting Reata to shift its focus to chronic kidney disease and diabetes. Bardoxolone activates the Nrf2 gene, improving the

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.